

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ASCENTAGE PHARMA GROUP INTERNATIONAL

亞盛醫藥集團

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6855)

(1) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR; AND (2) CHANGE IN COMPOSITION OF BOARD COMMITTEES

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Ascentage Pharma Group International (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce it has appointed Marc E. Lippman, MD (“**Dr. Lippman**”) as an additional independent non-executive Director of the Company with effect from January 2, 2025. As such, pursuant to the amended and restated articles of association of the Company (the “**Articles of Association**”), Dr. Lippman shall hold office until the first general meeting of the Company after his appointment, being the forthcoming annual general meeting of the Company (the “**AGM**”), and be subject to re-election by the shareholders of the Company (the “**Shareholders**”) at the AGM.

The biographical details of Dr. Lippman are set out as follows:

Marc E. Lippman, MD, aged 79, is a professor of Oncology and Internal Medicine at Georgetown University. Previously, Dr. Lippman was named the Kathleen and Stanley Glaser Professor of Medicine at the University of Miami Leonard M. Miller School of Medicine, and was named Chairman of the Department of Medicine in May 2007. Previously, Dr. Lippman was the John G. Searle Professor and Chair of Internal Medicine at the University of Michigan, Ann Arbor. Dr Lippman has served as Head of the Medical Breast Cancer Section, Medicine Branch, at the National Institutes of Health and was a Senior Investigator at the National Cancer Institute.

Dr. Lippman received his bachelor’s degree in Chemistry from Cornell University, magna cum laude, in June 1964 and medical school degree at Yale Medical School in June 1968. He completed his residency at the Osler Medical Service, John Hopkins Hospital and a Fellowship in Endocrinology at Yale Medical School. Dr. Lippman is widely known for his research in breast cancer. Throughout his career he has received numerous awards, including the First American Cancer Society Lectureship and Prize at the American Society of Clinical Oncology Meeting in Orlando, Florida in May 1993; the American Association for Cancer Research Rosenthal Award; and the Brinker Award for Basic Science of the Komen Foundation. Dr. Lippman also owns several patents.

Dr. Lippman is a member of the Association of American Physicians, the American Society for Clinical Investigation, the American Society of Biological Chemists, the American Association for Cancer Research and the American Society of Clinical Oncology. Dr. Lippman previously served on the board of directors of Seagen Inc., a public company which was acquired by Pfizer Inc. (NYSE: PFE). He is currently on the board of directors of Radiance Biopharma, Inc., a biotech start-up. As a researcher, Dr. Lippman has published over 500 peer-reviewed articles. In addition, he has authored many books and contributed many chapters based on his breast cancer research, including a textbook on breast disease. He has served on the editorial boards of numerous publications, including Breast Cancer Research and Treatment, for which he serves as editor-in-chief. He has previously been editor-in-chief of Endocrine-Related Cancer.

Dr. Lippman's appointment has been recommended by members of the nomination committee of the Company (the "**Nomination Committee**") and approved by the Board. Pursuant to the letter of appointment between Dr. Lippman and the Company, the term of service of Dr. Lippman shall be three years commencing on January 2, 2025, subject to retirement by rotation and re-election at the AGM in accordance with the Articles of Association, and Dr. Lippman will be entitled to a director's fee of USD60,000 per annum, which has been recommended by the remuneration committee of the Company and proposed by the Board with reference to, among other things, (i) his duties and responsibilities within the Company; (ii) the prevailing market conditions; and (iii) the continuous expansion of the business scale and continuously heightening requirements on corporate governance of the Company over recent years.

Dr. Lippman has confirmed that (i) he has satisfied all the criteria for independence as set out in Rule 3.13(1) to (8) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"); (ii) he has no past or present financial or other interest in the business of the Group or any connection with any core connected person (as defined in the Listing Rules) of the Company; and (iii) there are no other factors that may affect his independence at the time of his appointment.

Save as disclosed above, as at the date of this announcement, Dr. Lippman (i) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) has not held any other positions with the Company or other members of the Group; (iii) has not been a director of any public company, the securities of which are listed on any securities market in Hong Kong or overseas, in the last three years; (iv) does not have any other major appointments and professional qualifications; (v) does not have any relationship with any Director, senior management or substantial or controlling shareholders of the Company; (vi) has no other information that needs to be disclosed pursuant to paragraphs (h) to (v) of Rule 13.51(2) of the Listing Rules; and (vii) has no other matter that needs to be brought to the attention of the Shareholders.

The Board would like to take this opportunity to welcome Dr. Lippman for joining the Company.

CHANGE IN COMPOSITION OF BOARD COMMITTEES

The Board further announces that, in order to comply with the listing rules of The Nasdaq Stock Market LLC, with effect from January 2, 2025:

- (i) in connection with the Nomination Committee, Dr. Yang Dajun, Chairman and executive Director, will resign as the chairman, Dr. David Sidransky, an independent non-executive Director, will be re-designated as the chairman, and Marc E. Lippman, MD, an independent non-executive Director, will be appointed as a member. Following the abovementioned changes, the Nomination Committee will comprise Dr. David Sidransky (chairman), Mr. Ren Wei and Marc E. Lippman, MD;
- (ii) in connection with the audit committee of the Company (the “**Audit Committee**”), Mr. Ren Wei, an independent non-executive Director, will resign as a member, and Ms. Marina S. Bozilenko, an independent non-executive Director, will be appointed as a member. Following the abovementioned changes, the Audit Committee will comprise Mr. Ye Changqing (chairman), Dr. Lu Simon Dazhong and Ms. Marina S. Bozilenko; and
- (iii) in connection with the remuneration committee of the Company (the “**Remuneration Committee**”), Dr. Yang Dajun, Chairman and executive Director, will resign as a member, Dr. Debra Yu, an independent non-executive Director, will be appointed as a member. Following the abovementioned changes, the Remuneration Committee will comprise Mr. Ren Wei (chairman), Mr. Ye Changqing and Dr. Debra Yu.

By order of the Board
Ascentage Pharma Group International
Dr. Yang Dajun
Chairman and Executive Director

Suzhou, People’s Republic of China, January 2, 2025

As at the date of this announcement, the Board comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng and Dr. Lu Simon Dazhong as non-executive Directors, and Mr. Ye Changqing, Mr. Ren Wei, Dr. David Sidransky, Ms. Marina S. Bozilenko, Dr. Debra Yu and Marc E. Lippman, MD as independent non-executive Directors.